Compare VSAT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | VERA |
|---|---|---|
| Founded | 1986 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 3.2B |
| IPO Year | 1996 | 2021 |
| Metric | VSAT | VERA |
|---|---|---|
| Price | $81.32 | $35.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $59.80 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 1.8M | 909.4K |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.32 | N/A |
| Revenue Next Year | $3.57 | $472.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.28 | $19.07 |
| 52 Week High | $89.79 | $56.05 |
| Indicator | VSAT | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 65.28 | 46.16 |
| Support Level | $29.68 | $33.43 |
| Resistance Level | N/A | $42.77 |
| Average True Range (ATR) | 5.04 | 1.94 |
| MACD | 0.96 | 0.11 |
| Stochastic Oscillator | 67.50 | 38.42 |
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.